A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia
This is a prospective, multicenter, phase Ⅱ study consisting of dose escalation and ex-pansion stages in unfit newly diagnosed AML.
Trial Details
- NCT ID
- NCT07743112
- Phase
- PHASE2
- Sponsor
- Maxinovel Pty., Ltd.
- Status
- RECRUITING
- Cancer Type
- Leukemia
- Interventions
- MAX-40279
- Azacitidine
- Venetoclax
- Locations (sample)
- Tianjin, China|39.14222,117.17667
Key Eligibility Criteria
- 1\. Patients meeting the World Health Organization (WHO) 2016 diagnostic criteria for newly diagnosed acute myeloid leukemia (AML) patients unfit f…
- Age ≥65 years, or
- Age \>18 years and ineligible for standard-dose chemotherapy, defined by ≥1 of the following:
- ECOG performance status 2 or 3;History of chronic heart failure (CHF) requiring treatment or left ventricular ejection fraction (LVEF) ≤50% DLCO ≤6…
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →